C.R. Bard, Inc. (NYSE:BCR) VP John A. Deford sold 14,107 shares of the company’s stock in a transaction on Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
C.R. Bard, Inc. (NYSE BCR) opened at $332.28 on Friday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C.R. Bard, Inc. has a 1 year low of $220.84 and a 1 year high of $337.73. The firm has a market cap of $24,280.00, a price-to-earnings ratio of 43.78, a price-to-earnings-growth ratio of 2.53 and a beta of 0.52.
C.R. Bard (NYSE:BCR) last posted its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, topping the Zacks’ consensus estimate of $2.96 by $0.06. The firm had revenue of $989.80 million for the quarter, compared to analysts’ expectations of $990.64 million. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The business’s revenue for the quarter was up 5.1% on a year-over-year basis. During the same period in the prior year, the business posted $2.64 earnings per share. equities research analysts expect that C.R. Bard, Inc. will post 11.89 EPS for the current fiscal year.
BCR has been the topic of a number of analyst reports. Cowen reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Friday, November 3rd. Needham & Company LLC reiterated a “hold” rating on shares of C.R. Bard in a research report on Thursday, October 26th. Jefferies Group reiterated a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a research report on Thursday, September 14th. Barclays boosted their price objective on shares of C.R. Bard from $245.00 to $337.00 and gave the company an “equal weight” rating in a research report on Monday, November 6th. Finally, ValuEngine cut shares of C.R. Bard from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $303.50.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Monroe Bank & Trust MI grew its holdings in shares of C.R. Bard by 65.6% in the third quarter. Monroe Bank & Trust MI now owns 447 shares of the medical instruments supplier’s stock worth $100,000 after purchasing an additional 177 shares during the last quarter. Patten Group Inc. grew its holdings in shares of C.R. Bard by 66.0% in the third quarter. Patten Group Inc. now owns 556 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 221 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its holdings in shares of C.R. Bard by 70.4% in the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 460 shares of the medical instruments supplier’s stock worth $145,000 after purchasing an additional 190 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of C.R. Bard by 2.8% in the second quarter. Parallel Advisors LLC now owns 513 shares of the medical instruments supplier’s stock worth $164,000 after purchasing an additional 14 shares during the last quarter. Finally, Valeo Financial Advisors LLC bought a new position in shares of C.R. Bard in the third quarter worth about $170,000. Hedge funds and other institutional investors own 79.11% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.com-unik.info/2017/12/24/john-a-deford-sells-14107-shares-of-c-r-bard-inc-bcr-stock.html.
About C.R. Bard
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
What are top analysts saying about C.R. Bard? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for C.R. Bard and related companies.